8-K 1 tbuff_8k.htm CURRENT REPORT tbuff_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (date of earliest event reported): January 27, 2015
 
Tribute Pharmaceuticals Canada Inc.
(Exact Name of Registrant as Specified in its Charter)
 
         
Ontario, Canada
  
001-31198
  
Not Applicable
(State or Incorporation)
  
(Commission File Number)
  
(I.R.S. Employer Identification Number)
 
151 Steeles Avenue East, Milton, Ontario, Canada L9T 1Y1
(Address of principal executive offices) (Zip code)
 
(519) 434-1540
Registrant’s telephone number, including area code
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
Item 2.02
Results of Operations and Financial Condition
 
On January 27, 2015, the Company issued a press release announcing an update of 2014 revenues. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
 
The information in this Current Report on Form 8-K, including the exhibit attached hereto, is furnished pursuant to Item 2.02 and shall not be deemed to be "filed" for the purposes of Section 10 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
 
Item 9.01
Financial Statements and Exhibits.
 
d) Exhibits
 
The following exhibits are filed and furnished, respectively, herewith:
 
Exhibit
No.
  
Description
   
  
Press Release dated January 27, 2015
 
 
2
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Tribute Pharmaceuticals Canada Inc.
  
       
January 27, 2015
By:
/ s/ Scott Langille
  
   
Scott Langille
  
   
Chief Financial Officer
  
       
 
 
3
 
 
EXHIBIT INDEX
 
 
Exhibit
No.
 
Description
   
 
Press Release dated January 27, 2015
 
4